Skip to main content

Table 1 Characteristics of nasopharyngeal carcinoma patients with stage II-IVB

From: Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study

  ICRT arm (%) ICCCRT arm (%) P-value
Age (years)    0.55
 ≤ 54 years 69 (49.64) 42 (53.85)  
 > 54 years 70 (50.36) 36 (46.15)  
Sex    0.66
 Male 105 (75.54) 61 (78.21)  
 Female 34 (24.46) 17 (21.79)  
T category    0.21
 T1 61 (43.88) 33 (42.31)  
 T2 43 (30.94) 16 (20.51)  
 T3 20 (14.39) 16 (20.51)  
 T4 15 (10.79) 13 (16.67)  
N category    0.19
 N0 7 (5.04) 3 (3.85)  
 N1 47 (33.81) 19 (24.36)  
 N2 74 (53.24) 53 (67.95)  
 N3 11 (7.91) 3 (3.85)  
Clinical stage    0.13
 II 46 (33.09) 18 (23.08)  
 III 69 (49.64) 44 (56.41)  
 IVA 13 (9.35) 13 (16.67)  
 IVB 11 (7.91) 3 (3.85)  
IC regimen    0.11
 FP 16 (11.51) 13 (16.67)  
 TP 106 (76.26) 49 (62.82)  
 other 17 (12.23) 16 (20.51)  
IC cycles    0.78
 ≤ 2 cycles 81 (58.27) 47 (60.26)  
 > 2 cycles 58 (41.73) 31 (39.74)  
  1. IC induction chemotherapy, ICRT induction chemotherapy plus radiotherapy, ICCCRT concurrent chemotherapy plus radiotherapy, TP docetaxel/paclitaxel plus cisplatin, FP cisplatin plus fluorouracil